# ADEPPT (NCT05673187)

> Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05673187
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ETOP IBCSG Partners Foundation
- Conditions: NSCLC Stage IV; KRAS P.G12C
- Interventions: Adagrasib
- Enrollment: 68
- Primary outcome: Objective Response Rate (ORR) per RECIST v1.1, assessed at 12 weeks.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=adeppt-nct05673187